Status:
COMPLETED
An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients
Lead Sponsor:
AstraZeneca
Conditions:
Cardiovascular Disease
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to investigate the burden of upper gastrointestinal symptoms in patients with cardiovascular disease taking low dose aspirin
Eligibility Criteria
Inclusion
- Provision of signed written inform consent.
- Physician prescribed or recommended daily intake of Low Dose Aspirin (LDA) (75-325 mg daily) for cardiovascular disease prevention within the past 12 months.
- Established cardiovascular disease, such as CAD (CoronaryArtery Disease), previous TIA (Transient Ischemic Attack), ischemic stroke or subjects with known risk factors for cardiovascular disease without having experienced cardiovascular events
Exclusion
- Need for concomitant treatment with a non-ASA NSAID (Nonsteroidal Antiinflammatory Drugs) including acyclooxygenase-2 (COX-2) selective NSAID. Occasional use of up to 1 day/week is allowed.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
1836 Patients enrolled
Trial Details
Trial ID
NCT00681759
Start Date
January 1 2008
End Date
September 1 2008
Last Update
October 31 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Brentwood, Tennessee, United States
2
Research Site
Saint-Laurent, Quebec, Canada
3
Research Site
Paris, France